La catena delle opzioni mostra i dati chiave delle opzioni azionarie di iOThree a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per iOThree..

iOThree (NASDAQ:IOTR) Azioni, Catena delle Opzioni

iOThree Ltd is a company providing maritime digital technologies including satellite connectivity and digitalization solutions in Singapore focused on facilitating the maritime industry towards digital transformation. They have two operating segments which are satellite connectivity solution, and digitalization and other solutions. In the satellite connectivity solution segment, it offers integrated satellite connectivity solutions through the provision of satellite connectivity services and the sales and lease of satellite network equipment and devices for shipboard network management. In the digitalization and other solutions segment, They are involved in designing digital solutions, providing IT support, and providing shipboard support services for IT and OT applications enablement.

Wall-street-shutter3

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

GMGI

IOTR

Riflettori su titoli del settore comunicazione con RSI sotto 30. Golden Matrix, Outbrain e iOThree tra le società forse sottovalutate.

Queste 3 azioni tech gridano &#34;Compra ora&#34;? Parola agli esperti

Wall Street

L&#39;indicatore di forza relativa evidenzia due azioni del settore tecnologico e telecomunicazioni che potrebbero invertire la rotta.

2 titoli sottovalutati pronti al decollo? Ecco di chi si tratta

Mr. Cooper Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) has outperformed the market over the past 10 years by 6.03% on an annualized basis producing an average annual return of 17.58%. Currently, Mr. Cooper Gr has a market capitalization of $9.82 billion. 
Buying $1000 In COOP: If an investor had bought $1000 of COOP stock 10 years ago, it would be worth $4,953.84 today based on a price of $153.51 for COOP at the time of writing.
<h3>Mr. Cooper Gr's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751487571_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COOP

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Representative <a href="https://www.benzinga.com/topic/alexandria-ocasio-cortez">Alexandria Ocasio-Cortez</a> (D-NY) blasted the <a href="https://www.benzinga.com/news/financing/25/07/46215975/trumps-big-beautiful-bill-offers-seniors-a-6000-bonus-tax-deduction-heres-how-you-qualify-for-the-benefit">Trump administration&#8217;s proposed tax bill</a> during a session in the House of Representatives on Wednesday, sharply criticizing a provision that eliminates taxes on tips. She warned that the provision, which Trump has portrayed as a &#8220;pro-labor&#8221; initiative, does not live up to its promise when weighed against the other damaging aspects of the bill.
"On this point of tax on tips, as one of the only people in this body who has lived off of tips, I want to tell you a little bit about the scam of that text, a little bit of the fine print there," Ocasio-Cortez <a href="https://m.economictimes.com/news/international/world-news/to-give-musk-a-tax-break-alexandria-ocasio-cortez-explodes-at-trump-over-big-beautiful-bill/amp_podcast/122211707.cms">said</a>, addressing her colleagues. "The cap on that is $25,000. While you're jacking up taxes on people who make less than $50,000 across the United States while taking away their SNAP, while taking away their Medicaid, while kicking them off of the ACA and their health care extensions."
On Tuesday, Senate Republicans narrowly <a href="https://www.benzinga.com/news/politics/25/07/46211326/one-big-beautiful-bill-passes-senate-with-jd-vances-tie-breaking-vote-trump-says-its-going-to-go-very-nicely-in-the-house">passed</a> Trump&#8217;s massive tax and spending bill, which could add&nbsp;$3.3 trillion to the national&nbsp;debt. 
<h2 class="wp-block-heading">&#8216;Deal With The Devil&#8217; &#8211; Tax Cuts For Elon Musk, Other Billionaires</h2>
Ocasio-Cortez explained that while the provision might sound beneficial, it comes with hidden costs that could negatively affect low-income workers. She pointed to the stark choices facing workers who rely on tips to make a living. 
"So, if you're at home and you're living off tips, you do the math. Is that worth it to you? Losing all your health care? Not being able to feed your babies? Not being able to put a diaper on their bottom, in exchange for what?&#8221; 
She denounced the bill as a &#8220;deal with the devil,&#8221; arguing that it will only worsen the nation&#8217;s financial state by ballooning the national debt, militarizing the economy and stripping away basic services. &#8220;It explodes our national debt, it militarizes our entire economy, and it strips away health care and basic dignity of the American people for what? To give Elon Musk a tax break and billionaires the greedy taking of our nation? We can not stand for it, and we will not support it. You should be ashamed."
House Speaker Mike Johnson is working to meet a July 4 deadline.
Photo: Shutterstock

Government

Politics

Alexandria Ocasio-Cortez Bashes Trump's 'No Tax On Tips' Bill Provision As 'Scam'

Management

MCHP

Steve Sanghi Will Continue To Serve As Microchip CEO And President On A Permanent Basis

4 analysts have shared their evaluations of Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, accompanied by a high estimate of $17.00 and a low estimate of $13.00. Marking an increase of 3.39%, the current average surpasses the previous average price target of $14.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487492_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Elanco Animal Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Elanco Animal Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elanco Animal Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Elanco Animal Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Elanco Animal Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Elanco Animal Health analyst ratings.</a>
<h2>Delving into Elanco Animal Health's Background</h2>
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
<h3>Unraveling the Financial Story of Elanco Animal Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Elanco Animal Health's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -1.0%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Elanco Animal Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.08%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Elanco Animal Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.52%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Elanco Animal Health's debt-to-equity ratio is below the industry average. With a ratio of 0.69, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ELAN

The Analyst Verdict: Elanco Animal Health In The Eyes Of 4 Experts

In the last three months, 14 analysts have published ratings on Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Blackstone and provided 12-month price targets. The average target is $152.79, accompanied by a high estimate of $207.00 and a low estimate of $129.00. Observing a downward trend, the current average is 13.11% lower than the prior average price target of $175.85. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487483_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Blackstone. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$153.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$139.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$136.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$139.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$129.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$207.00</td>
<td>$219.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Blackstone. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blackstone compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Blackstone's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Blackstone's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blackstone analyst ratings.</a>
<h2>Discovering Blackstone: A Closer Look</h2>
Blackstone is the world's largest alternative-asset manager with $1.167 trillion in total asset under management, including $860.1 billion in fee-earning assets under management, at the end of March 2025. The company has four core business segments: private equity (26% of fee-earning AUM and 30% of base management fees), real estate (34% and 40%), credit and insurance (32% and 23%), and multi-asset investing (8% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
<h3>Blackstone: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Blackstone's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -7.28%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Blackstone's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 21.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blackstone's ROE stands out, surpassing industry averages. With an impressive ROE of 7.6%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Blackstone's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Blackstone's debt-to-equity ratio surpasses industry norms, standing at 1.68. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Blackstone: 14 Analysts Share Their Views

13 analysts have expressed a variety of opinions on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.46, a high estimate of $52.00, and a low estimate of $18.00. Highlighting a 17.68% decrease, the current average has fallen from the previous average price target of $37.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487475_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Deschner</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Apellis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Apellis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Apellis Pharmaceuticals Better</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Apellis Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Apellis Pharmaceuticals's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.21%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -55.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -46.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.9%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 2.86, Apellis Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals

WIIM

Inovio shares are trading lower after the company announced a proposed public offering.

On June 3, 2025, a director of Baosheng Media Group Holdings Limited (the "Company") was served with a complaint filed by three institutional investors (the "Plaintiffs") in the Beijing Fourth Intermediate People's Court. The Plaintiffs allege that five defendants, including the director, engaged in corporate mismanagement that caused a significant decline in the value of the Company's stock held by the Plaintiffs, resulting in substantial investment losses. The Plaintiffs are seeking damages of RMB 47,249,848 (approximately US$6.59 million). The five defendants have retained legal counsel to file their defense.

Legal

BAOS

Baosheng Media Director Named In ~$6.6M Lawsuit By Institutional Investors Alleging Corporate Mismanagement

General

Enterprise Products Partners Receives Letter From BIS  Indicating Intention To Rescind License Requirements For Ethane Export To China

STEM

Stem Appoints Brian Musfeldt As CFO, Succeeding Doran Hole, Effective July 17, 2025

Offerings

INOVIO Announces Proposed Public Offering, Size Not Disclosed

HOOD

MSFT

OpenAI Posts On X "These "OpenAI tokens" are not OpenAI equity. We did not partner with Robinhood, were not involved in this, and do not endorse it.  Any transfer of OpenAI equity requires our approval—we did not approve any transfer. Please be careful."

XHLD

TEN Holdings Receives Nasdaq Noncompliance Letter

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) lowers FY2025 sales outlook from $275.000 million-$285.000 million to $265.000 million-$275.000 million vs $276.547 million estimate.

Guidance

Franklin Covey Lowers FY2025 Sales Guidance from $275.000M-$285.000M to $265.000M-$275.000M vs $276.547M Est

Cango, Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) shares are trading higher on possible continued strength after the company announced yesterday that it produced 450 Bitcoins for the <a href="https://www.benzinga.com//node/46190207">month of June.</a>
What To Know:&nbsp;The company reported mining 450 Bitcoin in June, down from 484.5 Bitcoin in May. Average daily production fell slightly to 15 Bitcoin from 15.63 Bitcoin in the prior month.
Cango ended June with 3,879.2 Bitcoin in total holdings, up from 3,429.3 Bitcoin at the end of May. The company did not sell any Bitcoin during the month.
Cango maintained a deployed hashrate of 32 EH/s and reported an average operating hashrate of 29.92 EH/s in June. On June 27, the company completed the acquisition of additional mining machines, increasing total hashrate to 50 EH/s.
CANG Price Action: Cango stock closed Wednesday 12.13% higher at $5.27, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwii7Z7y656OAxUBFVkFHQpbAFEQFnoECA4QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
See Also: •. <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46229237/cash-rich-ionq-to-capture-20-of-quantum-market-by-2035-analyst">Cash-Rich IonQ To Capture 20% Of Quantum Market By 2035</a>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

CANG

Cango Stock Is Rising Wednesday: What's Going On?

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.04) by 197.3 percent. This is a 125.58 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $67.121 million which missed the analyst consensus estimate of $67.491 million by 0.55 percent. This is a 8.52 percent decrease over sales of $73.373 million the same period last year.

Earnings

Earnings Misses

Franklin Covey Q3 EPS $(0.11) Misses $(0.04) Estimate, Sales $67.121M Miss $67.491M Estimate

SOHO

Sotherly Hotels shares are trading lower after the company announced it received a notice of default for its mortgage loan.

Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), maker of the world's most advanced electric vehicles, today announced production and delivery totals for the quarter ended June 30, 2025. During this period, Lucid produced 3,863 vehicles and delivered 3,309 vehicles. During the six months ended June 30, 2025, Lucid produced 6,075 vehicles and delivered 6,418 vehicles.

LCID

Lucid Group Produces 3,863 Vehicles And Delivers 3,309 In Q2 2025; Produces 6,075 Vehicles, Delivers 6,418 in H1 2025

Even as U.S. stocks trade at all-time highs, JPMorgan's new mid-year outlook suggests a quiet storm may be forming under the surface—one that could see gold soar, the dollar weaken, and markets reset in the <a href="https://www.benzinga.com/topic/expert-ideas">second half of 2025.</a>
<h3 class="wp-block-heading">S&amp;P 500 May Cool Off—But Not Crash</h3>
In a report shared Tuesday, the investment bank forecasted the S&amp;P 500 — as tracked by the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) — to finish the year at 6,000, implying a modest 3.5% pullback from current levels around 6,220.
That would still mark a positive year overall, underpinned by a 12% increase in earnings, with further growth expected in 2026.
"The economy and consumers have shown resilience, and corporates delivered healthy pre-Liberation Day growth of 12% despite the implied aggregate tariff rate surpassing 20%," said Dubravko Lakos-Bujas, head of Global Markets Strategy at JP Morgan.
Yet there are reasons for caution. "We remain open to the economy slowing in the second half of this year at a time when valuation is less supportive," he said, noting that the market may repeat the pattern seen in 2023–2024: narrow leadership and high concentration.
<h3 class="wp-block-heading">US Growth Outlook Trimmed, Inflation Risks Rising</h3>
Inflation is expected to heat up again during the summer months. This could push the Fed's next rate cut to December, according to JPMorgan economists.
"We anticipate this [tariff] shock to generate a broad-based downshift in global growth and a rotation in inflation pressures toward the U.S.," said Bruce Kasman, chief economist. 
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46205961/bitcoin-vs-gold-which-is-better-in-2025">Gold Rarely Beats Bitcoin, But 2025 Could Be Another Blowout Year</a>
<h3 class="wp-block-heading">Gold Rally Not Over—Could Hit $4,000 By 2026</h3>
Gold's bullish trend is far from over, with JPMorgan forecasting the metal to average $3,675 per ounce in the fourth quarter of 2025 and potentially exceed $4,000 by the second half of 2026.
"For investors, we think gold remains one of the most optimal hedges for the unique combination of stagflation, recession, debasement and U.S. policy risks," said Natasha Kaneva, head of Global Commodities Strategy.
If JPMorgan&#8217;s gold forecast plays out, the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) could climb another 10% by year-end and gain up to 20% more through mid-2026, tracking bullion's surge toward $4,000.
Meanwhile, oil prices are likely to stay subdued due to a growing supply surplus. Kaneva said JPMorgan sees Brent crude trading in the low-to-mid $60s per barrel through the end of the year, barring a severe Middle East escalation.
<h3 class="wp-block-heading">A Weaker Dollar Supports EM Currencies</h3>
JPMorgan remains bearish on the U.S. dollar amid shifting global dynamics. "The main anchors of our bearish USD view remain unchanged," said Meera Chandan, co-head of Global FX Strategy.
Chandan pointed to fading U.S. growth exceptionalism, expensive valuations, and a buildup of liabilities relative to the rest of the world. 
"Several key conditions seem to define the onset of a USD bear cycle&#8230; Plus, past experience indicates that once initiated, dollar bear cycles can persist for a while," she said.
This environment supports emerging market currencies, which are expected to outperform in the second half. 
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46171994/emerging-markets-stocks-dollar-outlook">A Weaker Dollar Just Unlocked A Surprise 2025 Winner — And Smart Money Is Moving In </a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

Something Big Is Brewing In Gold, Stocks, And The Dollar: JPMorgan's Half-Year 2025 Outlook

Biotech

IART

Integra LifeSciences Announces First Patient Has Enrolled In Acclarent AERA Pediatric Registry

IPOs

Press Releases

iOThree Limited Announces Pricing of Initial Public Offering

iOThree Limited Announces Closing of Initial Public Offering

F.R.I.D.A.Y Planned Maintenance System Receives ClassNK Approval, Advancing Maritime Digitalization

Deckhouse Communications and iO3 Collaborate to Bring Advanced Digital Solutions to Turkish Maritime Sector

iOThree Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Singfar Group Embraces Digitalization with iO3's V.Sight AI Video Analytics for Vessel Surveillance

AST SpaceMobile, Inc. - Class A Common Stock

AST SpaceMobile

Anterix

Bandwidth

Cogent Communications Holdings, Inc. - Common Stock

Cogent Comms Hldgs

Globalstar

iOThree

iQSTEL

Iridium Communications Inc - Common Stock

Iridium Communications

Liberty Global Ltd. - Class A Common Shares

Liberty Global

Liberty Global Ltd. - Class C Common Shares

Liberty Latin America Ltd. - Class A Common Stock

Liberty Latin America

Liberty Latin America Ltd. - Class C Common Stock

Lumen Technologies

NextPlat

Sify Technologies Limited - American Depository Shares, each represented by one Equity Share

Comments

iOThree

iOThree (IOTR) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO